VRTX Q2 2021 Earnings — Vertex Pharmaceuticals Incorporated Revenue & Financial Results | Market Cap Arena

VRTXVertex Pharmaceuticals Incorporated

$125B

Q2 2021 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$1.8B+17.6% YoY

Gross Profit

$1.6B87.3% margin

Operating Income

-$38M-2.1% margin

Net Income

$67M3.7% margin

EPS (Diluted)

$0.26

QoQ Revenue Growth

+4.0%

Cash Flow

Operating Cash Flow

-$200M

Free Cash Flow

-$250M

Stock-Based Comp.

$105M

Balance Sheet

Total Assets

$12.2B

Total Liabilities

$3.0B

Stockholders' Equity

$9.2B

Cash & Equivalents

$6.1B

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$1.8B	$1.5B	+17.6%
Gross Profit	$1.6B	$1.3B	+16.8%
Operating Income	-$38M	$718M	-105.3%
Net Income	$67M	$837M	-92.0%

Revenue Segments

TRIKAFTA/KAFTRIO

$1.3B70%

ORKAMBI

$221M12%

KALYDECO

$183M10%

SYMDEKO/SYMKEVI

$134M7%

Geographic Segments

UNITED STATES

$1.3B70%

Europe

$459M26%

Other, Non U.S.

$78M4%